

ORIGINAL ARTICLE

Delphi consensus on melasma management by international experts and pigmentary disorders society

Rashmi Sarkar¹  | Seemal R. Desai^{2,3}  | Surabhi Sinha¹  | Sunil Dogra⁴  |
 María-Ivonne Arellano-Mendoza⁵ | Pallavi Ailawadi⁶ | Sanjeev Aurangabadkar⁷ |
 Edileia Bagatin⁸ | Shyamanta Barua⁹ | Mala Bhalla¹⁰ | Daniel Cassiano⁸ | Tania Cestari¹¹ |
 Anupam Das¹²  | Johannes Dayrit¹³ | Ncoza Dlova¹⁴ | Cheng-Che E. Lan¹⁵  |
 Nada Elbuluk¹⁶ | Ana Cláudia Espósito¹⁷ | Evangeline Handog¹⁸  | Soumya Jagadeesan¹⁹ |
 Saloni Katoch²⁰ | Muthu Sendhil Kumaran⁴  | Prasad Kumarasinghe²¹ |
 Maria Juliet Macarayo²² | Helio A. Miot²³  | Venkataram Mysore²⁴ | Vignesh Narayan R²⁵  |
 Sang Ho Oh²⁶  | Thierry Passeron²⁷  | Mauro Picardo²⁸  | Indrashis Podder²⁹  |
 Soumya Sachdeva³⁰ | Aseem Sharma³¹  | Richa Sharma³² | Vijay Somani³³ |
 Bhavesh Swarnkar³⁴ | Susan Taylor³⁵ | Devinder Mohan Thappa³⁶ | Keshavamurthy Vinay⁴  |
 Henry W. Lim³⁷

Correspondence

Rashmi Sarkar, Department of Dermatology,
Lady Hardinge Medical College & Associated
SSK and KSC Hospitals, Shaheed Bhagat
Singh Marg, Lady Hardinge Medical College,
DIZ Area, Connaught Place, New Delhi, Delhi
110001, India.
Email: rashmisarkar@gmail.com

Funding information

Galderma India Pvt Ltd

Abstract

Background: Melasma, an acquired hyperpigmentation disorder, affects individuals of all ethnicities. Its multifactorial aetiology, high recurrence rates and psychosocial impact complicate management and necessitate comprehensive, evidence-based recommendations.

Objectives: The objective was to develop an international consensus on the diagnosis and management of melasma by synthesizing expert opinions and the latest scientific evidence.

Methods: This consensus was developed through a series of 7 (30.9% [1.5 (i)-19.7 (ng e) 4.8 (e) Me-30.9 (h) 4.8 (e) 10.6 (r) 5.0 (o) 4.47 (c)-106 (e)-11 (.s)-10.8 (s)-1 (4, e)-26.5 (n) 6.7 (c) rounds of surveys and discussions, under the aegis of the Pigmentary Disorders Society (PDS). A literature search of articles published between 2014 and 2024 identified key studies that were graded using the Oxford levels of evidence (2009). Consensus statements were drafted, refined and finalized based on expert feedback. Responses were assessed using a 5-point Likert scale, with predefined thresholds for high ($\geq 75\%$), moderate (55%–74%) and low ($< 55\%$) agreement.

Results: The consensus development process started with 34 statements, and at the end of the third round of the Delphi process, 21, 4 and 1 statement reached high, moderate and low consensus, respectively. Key recommendations highlighted photoprotection with broad-spectrum sunscreens as essential, regulated and supervised

INTRODUCTION

Melasma is an acquired disorder of hyperpigmentation that affects individuals across all ethnicities, although its prevalence is particularly pronounced in darker skin types and photoexposed populations.¹ While the condition can occur

METHODS

This study was conducted to develop international consensus-based recommendations for managing melasma, focusing on recent advancements in the field. A modified Delphi approach was employed. Figure 1 shows an overview of the workflow. While this study was not prospectively registered, it adhered to a transparent process in alignment with established consensus development practices.

The Core Group and selection of members for voting

The core group comprised two senior members from the PDS with extensive experience in dermatology and melasma research. Their responsibilities included designing, moderating and overseeing the consensus process. A diverse panel of 20 members from PDS, along with 18 international dermatology experts (38 total) from various clinical and geographic backgrounds, was invited to participate in the process (Table S1). These experts were selected based on their contributions to melasma research, clinical experience and publications on this topic of interest. The core group did not participate in the voting to avoid potential bias.

Literature search

A search of the PubMed database was conducted to identify studies published between 2014 and 2024. The search strategy

included structured queries focused on topics such as melasma management, diagnosis and treatment (as outlined in Table S2). Studies were screened for inclusion based on methodological rigor, prioritizing randomized controlled trials (RCTs), systematic reviews, cohort studies and meta-analyses. Articles meeting these criteria were graded using the Oxford level of evidence framework (2009). A summary of the literature search was shared with the expert panel as a pre-read.

Review of evidence and formulation of consensus statements

The literature review helped identify evidence-based practices and knowledge gaps in melasma management. Broad domains, such as diagnosis, treatment options and maintenance strategies, were determined. Consensus statements were drafted, which underwent several revisions based on expert feedback.

Administering the questionnaire, gathering responses and aggregating results

A questionnaire was developed to collect expert opinions and administered to the panel using an online survey platform. Responses were gathered anonymously on a 5-point Likert scale (strongly agree, agree, neither agree nor disagree, disagree and strongly disagree). Responses were quantified based on predefined levels: high agreement ($\geq 75\%$ of respondents voted agree/strongly agree or disagree/strongly disagree), moderate agreement (55%–74%)




FIGURE 1 Overview of the workflow for the consensus-building process.

and low agreement (<55%). Statements were retained, revised or removed based on feedback. Consensus statements that did not receive high or moderate agreement and had a substantial number of 'neither agree nor disagree' responses were identified as areas where evidence remains inconclusive, highlighting the need for further research. The study materials and survey instruments were designed to be clear and focused. Separate piloting prior to dissemination was not conducted.

Consensus development process

The consensus development process followed a modified Delphi methodology involving voting and discussions. The first round involved voting on the initial set of consensus statements. A virtual meeting was then convened to discuss statements requiring further deliberation. During this meeting, panellists deliberated whether to retain, revise or remove such statements. Following the discussions, revised statements were subjected to a second round of voting. Statements achieving high agreement were finalized, and additional feedback was incorporated to address any remaining divergent views. This process ensured that the final recommendations reflected current evidence and clinical experience.

RESULTS

The consensus process was carried out between June and December 2024. The participants were provided 15 days

to complete each round of the survey. The participation rate in the first two rounds was 100% ($n=38$). In the final round, 29 participated in the virtual meeting, and the remaining shared their inputs via email. A total of 34 statements were drafted for voting and discussions. The voting results were then discussed. Eight statements (five with moderate consensus and three with low consensus) were removed after discussion. This elimination followed the expert panel's judgement that the statement relied on limited or conflicting data, overlapped substantially with better-supported recommendations, or when described interventions were not widely available or had unresolved safety concerns. Removing said statements allowed the final set to reflect only those practices backed by robust evidence and broad clinical applicability, thereby strengthening the clarity of the consensus document. In the second round of voting and discussion, panel members were given the option to add their opinions on the online voting platform. At the end of the consensus process, 21, 4 and 1 statement reached high, moderate and low consensus, respectively. Figure 2 summarizes the results of the voting and discussion. The finalized consensus statements are provided in Table 1.

DISCUSSION

Melasma is a complex and recurrent condition with high relapse rates, which underscores the need for strategies that address its multifactorial pathogenesis and proactive strategies for prevention of relapses. The main mechanisms implicated




FIGURE 2 Summary of three rounds of voting.

TABLE 1 Finalized consensus statements.

Sl. no.	Finalized consensus statement	Level of evidence	Finalized in round	Final level of consensus
Diagnostic and monitoring tools				
1	Wood's lamp remains a favoured method for determining the extent and severity of melasma	5	3	High
2	Dermoscopic examination is an accepted non-invasive tool that can facilitate the differential diagnosis of melasma from similar conditions	2b, 5	2	High
3	Treatment monitoring with reflectance confocal microscopy enables the objectification of pigment variations after treatment and the identification of prognostic factors for different treatment modalities	2a	2	Moderate
4	Occasionally, melasma may appear like another hyperpigmentary condition. In such cases, a skin biopsy with histopathological examination is needed to confirm the diagnosis	5	1	High
Photoprotection				
5	The characteristics of an ideal sunscreen should include broad-spectrum coverage with protection against UVA, UVB and visible light, an optimal sun protection factor and cosmetic acceptability	4, 5	3	High
6	The addition of active ingredients such as antioxidants, depigmenting and moisturizing agents to sunscreen can increase its efficacy in managing melasma and enhance the skin's tolerability to topical treatments	5	2	Moderate
Topical agents				
7	Triple combination therapy (hydroquinone, tretinoin and fluocinonide acetone) is the gold standard for the management of melasma and may be used as a first-line option	1b, 1a	2	High
8	Unsupervised use of triple combination therapy is not recommended, and proper precaution should be used	5, 5	2	High
9	The duration of intensive daily treatment with triple combination cream (TCC) can be up to 12 weeks. However, treatment variations may be patient-dependent	2b	2	High
10	The twice-weekly regimen of triple combination cream is effective for melasma and can be followed by tapering to other topical agents after the initial period of treatment	1b	1	High
11	Azelaic acid can serve as an effective treatment option for melasma patients with concerns about the adverse effects of hydroquinone	1a	1	High
12	Antioxidants such as topical vitamin C can be beneficial in managing melasma	1a	1	High
13	Combinations with ingredients such as kojic acid, arbutin, vitamin E and other botanical ingredients may be used as additional options	2b	3	High
Oral agents				
14	Oral tranexamic acid is effective in the management of melasma	2b, 5	3	High
15	Oral antioxidants, in combination with other appropriate treatment modalities, can serve as an option for the management of melasma	1b, 2b, 4	3	High
Chemical peels				
16	Glycolic acid is the most studied peel and shows superior outcomes compared to others. Other options include salicylic acid peels, retinoic acid peels, trichloroacetic acid (TCA) peels (low concentration) and Jessner's peels	2a	2	High
17	Glycolic acid and salicylic-mandelic acid peels have comparable efficacy and are well tolerated	1b	2	Moderate
18	Some of the refractory melasma can be treated by using a combination of a depigmenting agent (4% hydroquinone/TCC) and a peeling agent	4, 1b, 1b	1	High
19	Combination peels may be used as an additional option for the treatment and maintenance of melasma	2b	2	High
Energy-based devices and procedural treatments				
20	A low-fluence Q-switched Nd:YAG laser can be a suitable option for refractory cases of melasma	2a, 5	2	High
21	Vascular abnormalities have been implicated in melasma. There is promising evidence supporting the use of tranexamic acid and laser/light therapies to target the vascular component of melasma	2a	2	High

in melasma include inappropriate activation of melanocytes, aggregation of melanin and melanosomes in both the dermis and epidermis, increased mast cell count and solar elastosis, altered basement membrane integrity and increased vascularization.² Understanding these pathophysiological mechanisms is critical for selecting appropriate treatment modalities.

radiation are significant contributors to its pathogenesis.¹³ However, poor adherence to photoprotection, more so among high-risk groups, remains a challenge.^{13,14}

Cosmetic elegance and tone compatibility have been indicated as important considerations for sunscreen (e)-9.1 (e.9 0 11 (a

Diagnosis and monitoring (Statements 1–4 in Table 1)

The diagnosis of melasma can be challenging due to its clinical resemblance to other hyperpigmentation disorders. The panel agreed that Wood's lamp remains a favoured method for determining the extent and severity of melasma, but the constraints in accurately determining melanin depth may limit its use.⁸ Although the utility of dermoscopy in the determination of depth has been contested, the expert panel felt that it is an accepted and non-invasive tool that can facilitate the differential diagnosis.^{9,10} Though some authors suggest considering the intradermal component of melasma during diagnosis and treatment planning,¹¹ the panel discussion highlighted that therapeutic choice depends not so much on the depth as on the severity of melasma. The limited availability of reflectance confocal microscopy outside of research establishments was pointed out. However, its utility, when available, was acknowledged. A skin biopsy may be needed to confirm melasma in cases with close differential diagnosis. Histopathological findings typically show epidermal hyperpigmentation with hypertrophied melanocytes, increased melanin and mature melanosomes. The dermis can exhibit melanin-laden macrophages along with mononuclear infiltrates, increased vascularity, mast cells and elastosis.¹²

Treatment

Photoprotection (Statements 5, 6 in Table 1)

Photoprotection remains the cornerstone of melasma management, as high-energy visible light and ultraviolet

(TCCs). It is often combined with other agents to enhance efficacy but requires close supervision due to rare yet significant risks like exogenous ochronosis. Hydroquinone can be applied evenly over the affected areas and used concurrently with sunscreen to protect from damaging UV light, which increases pigmentation. If there are no results after 3 months, hydroquinone should be discontinued. It is prudent to stop hydroquinone-containing creams for a few months before restarting to decrease the risk of side effects. It can also be used during weekends only or three times a week for more extended maintenance therapy with minimal complications. TCC, incorporating hydroquinone (4%), tretinoin (0.05%) and fluocinolone acetonide (0.01%), is regarded as the gold standard for melasma treatment and remains a first-line therapy. Although 4% is the standard, the use of TCC with a lower concentration of hydroquinone (2%) has also been reported. TCC formulations using different corticosteroids have shown efficacy. However, it has been indicated that fluorinated steroids (e.g., fluocinolone acetonide) are more effective and safer than non-fluorinated steroids.²⁷ TCC containing fluocinolone acetonide 0.01% has been shown to be as effective as mometasone furoate 0.1% with fewer side effects.²⁸ Treatment typically lasts up to 12 weeks, followed by a maintenance regimen, though the duration may vary. A twice-weekly regimen after intensive treatment and tapering to other topicals was suggested.²⁹ The expert panel emphasized that the TCC should only be used under clinical supervision, and proper precautions should be taken. Although TCC is recommended as first-line treatment, the expert panel agreed on azelaic acid as an option for those with concerns about adverse effects. Azelaic acid exhibits anti-inflammatory properties, making it a promising alternative to treatments that primarily target melanin production without addressing inflammation.³⁰ Azelaic acid-containing creams at concentrations of 15%–20%, twice daily for 6 months, have been recommended.³¹ There was high consensus on the use of topical antioxidants, such as vitamin C, for melasma management. The benefits of topical vitamin C in the management of melasma and photoaging have been reported.³² Such a dual role is noteworthy in light of evidence on pathophysiology suggesting melasma as a photoaging disorder.³³ For reasonable results, it has been suggested that a vitamin C concentration higher than 8% n3TJ rg/GS0 gs0.013 Tc -0-3.005w -23.005 134.9081 215t9 5575 6443

Chemical peels (Statements 16–19 in Table 1)

Chemical peels increase epidermal exfoliation and also target the dermal component of melasma by inducing phagocytosis of melanin granules. The expert panel agreed that, among other peels, glycolic acid is the most studied and shows superior outcomes.⁵² This recommendation augments the previous Latin American consensus, which suggests a lack of clear evidence of superiority, but is in line with the Chinese consensus that supports the effectiveness of alpha hydroxy acid peels.^{31,40} Serial glycolic acid peels enhance the efficacy of the topical regimen with a more rapid initial response and overall lightening of the skin.

In trials, glycolic acid has most commonly been used at 30%–50% concentrations, with higher strengths (up to 70%) also reported.^{53–56} Higher concentrations may be suited for spot peels only under expert supervision. The utility of other options, such as salicylic acid (20%–30%),⁵⁴ retinoic acid (1%–10%),^{57,58} trichloroacetic acid (low concentration of 10%–35%)⁵⁹ and Jessner's peels, was also acknowledged. Combining depigmenting agents such as 4% hydroquinone or TCC with chemical peels can enhance treatment outcomes for refractory melasma. Chemical peels promote controlled exfoliation, facilitating deeper penetration of topical agents and improving skin texture.^{60,61} However, it has been recommended that medium-depth peels should be avoided.³¹ The panel was also in favour of combination peels as an additional option for the treatment and maintenance of melasma. The agreement was moderate regarding whether glycolic acid and salicylic–mandelic acid peels have comparable efficacy. Some evidence reports that glycolic acid and salicylic–mandelic acid (20% salicylic/10% mandelic acid) peels are equally effective and provide better outcomes than phytic acid combination peels.⁶² However, the scarcity of studies with head-to-head comparisons of different peels was pointed out.

Laser or energy-based devices and procedural treatments (Statements 20–24 in Table 1)

Laser treatment of melasma is at best a third-line therapy. Q-switched Nd:YAG laser (1064 nm) in toning mode is preferred for its selective melanin targeting with minimal complications.^{63,64} Laser or energy-based devices, including Q-switched Nd:YAG lasers, picosecond lasers, intense pulsed light (IPL), pulsed dye laser (PDL) and radiofrequency, show efficacy but carry risks of relapse and adverse effects.⁶ Though effective, the panel expressed that laser therapies require careful patient selection and are best reserved for refractory cases.^{63–66} The expert consensus emphasized laser therapy as an adjunct rather than monotherapy, supported by meta-analysis data.⁶⁵ The potential of lasers to improve the delivery of topical agents to the target site has been reported.^{65,67} There was high consensus that TA can be combined with laser/light therapies to treat the vascular component of melasma.⁶⁸

Microneedling improves transcutaneous drug delivery and can be considered a step-up option before invasive

procedures.⁶⁹ The discussion highlighted that microneedling promotes collagen production and remodelling of the dermal matrix and can serve as an additional procedural option. Evidence from an RCT suggests that both microneedling and TA improve the performance of TCC, with microneedling providing sustained remission.⁷⁰ Studies have shown that microneedling with 5% TA is effective.⁴⁵ The findings from a systematic review and meta-analysis also suggest that among various routes of TA delivery, intradermal injection and microneedling can be effective alternatives for melasma treatment.⁷¹ However, the expert panel expressed the need for more studies confirming improvements in transcutaneous drug delivery, and the statement reached a moderate consensus. Several studies and RCTs suggest that 4

include glutathione in this consensus, but clinicians should be prepared to counsel patients on its uncertain effectiveness and IV-related safety concerns.

Adjunct therapies and skincare (Statement 26 in [Table 1](#))

Cosmeceuticals enriched with bio-actives, plant extracts, and hydrating agents can improve tolerability and compliance.^{22,83} Skin care products often contain ingredients that help repair the skin barrier, which is crucial as impairment of the skin barrier can exacerbate melasma. When combined with treatments such as chemical peels or lasers, they can enhance efficacy and patient satisfaction. Moisturizers help restore the compromised skin barrier in melasma. While transdermal epidermal water loss in melasma lesions is similar to the surrounding skin, the barrier recovery rate in lesional skin is significantly slower, leading to reduced moisturizing capabilities and forming a vicious cycle.²²



management of melasma, drawing on the latest evidence and expert opinions. By integrating these guidelines, dermatologists can optimize outcomes and improve patients' quality of life. A simplified algorithm summarizing the outcomes from the panel discussion is presented in [Figure 3](#). Future research is needed to validate therapies and reduce recurrence.

AUTHOR CONTRIBUTIONS

All authors made substantial contributions to the conception or design of the work and participated in the critical review and editing of the manuscript for important intellectual content. Additionally, data curation and formal analysis were conducted by Dr. Rashmi Sarkar and Dr. Seemal R. Desai. All authors approved the final version of the manuscript to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

AFFILIATIONS

¹Department of Dermatology, Lady Hardinge Medical College & Associated SSK and KSC Hospitals, New Delhi, India

²Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

³Innovative Dermatology, Plano, Texas, USA

⁴Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

⁵Department of Dermatology, Hospital Dalinde, Mexico City, Mexico

⁶Department of Dermatology, Skinacea Clinic, Faridabad, India

⁷Dr Aurangabadkar's Skin & Laser Clinic, Hyderabad, India

⁸Department of Dermatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil

⁹Department of Dermatology, Assam Medical College & Hospital, Dibrugarh, India

¹⁰Department of Dermatology, Venereology and Leprology, Government Medical College and Hospital Sector 32, Chandigarh, India

¹¹Department of Dermatology, University of Rio Grande Do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

¹²Department of Dermatology, KPC Medical College and Hospital, Kolkata, India

¹³Department of Dermatology, De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines

¹⁴Department of Dermatology, University of KwaZulu-Natal, Durban, South Africa

¹⁵Department of Dermatology, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

¹⁶Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

¹⁷Department of Dermatology, Unesp Medical School and Uneste, Presidente Prudente, Brazil

¹⁸Department of Dermatology, Asian Hospital and Medical Center, Muntinlupa, Philippines

¹⁹Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, India

²⁰Department of Dermatology, Venereology and Leprosy, Dr. KN Barua Institute of Dermatological Sciences, Guwahati, India

²¹Department of Dermatology, Western Dermatology, Perth, Western Australia, Australia

²²Department of Dermatology, Angeles University Foundation Medical Center, Angeles City, Philippines

²³Department of Dermatology, Unesp Medical School, Botucatu, Brazil

²⁴Department of Dermatology, Venkat Center for Skin and Plastic Surgery, Bangalore, India

²⁵Department of Dermatology, Venereology and Leprology & Dermatotomy, Bangalore Medical College and Research Institute, Bangalore, India

²⁶Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

²⁷Department of Dermatology, CHU Nice, Cote d'Azur University, Nice, France

²⁸Department of Dermatology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy

²⁹Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, India

³⁰Department of Dermatology, Venereology and Leprology, Saraswathi Institute of Medical Sciences, New Delhi, India

³¹Department of Dermatology, Skin Saga Centre for Dermatology, Mumbai, India³¹

Honoraria), Estée Lauder (Advisory Board Honoraria), Evolus, Inc. (Advisory Board Honoraria), Galderma Laboratories, L.P. (Advisory Board Honoraria), GloGetter (Consultant Stock Options), HMP Global (Speaker for CME credit Honoraria), Hugel America, Inc. (Advisory Board Honoraria), Incyte (Advisory Board Honoraria), Johnson & Johnson Innovative Medicine (Advisory Board Honoraria), LearnSkin (Speaker for CME credit Honoraria), L'Oréal USA (Advisory Board Honoraria), Medscape/WebMD (Speaker for CME credit Honoraria; Advisory Board Honoraria), MJH LifeSciences (Speaker for CME credit Honoraria), Pfizer (Advisory Board Honoraria), Piction Health (Consultant Stock Options), Sanofi (Consultant Honoraria), Scientist US (Advisory Board Honoraria), UCB (Advisory Board Honoraria) and Vichy Laboratoires (Advisory Board Honoraria). Dr. Susan Taylor also receives book royalties from McGraw-Hill and serves on the editorial boards of Practical Dermatology, Cutis and Archives in Dermatologic Research. She is a peer reviewer for the British Journal of Dermatology. Additionally, she has received investigator-initiated research grants from Allergan Aesthetics, Concert Pharmaceuticals/Sun Pharma, Croma-Pharma GmbH, Eli Lilly and Pfizer. Dr. Helio A. Miot – Advisory and speaker from Galderma, Kenvue, L'Oréal, Pfizer, Theraskin, and Beiersdorf. Investigator honoraria from AbbVie, Pierre-Fabre, Galderma, Theraskin. All authors disclosed relationships with pharmaceutical companies. Dr. Henry W Lim served as an investigator for Incyte, La Roche-Posay, Pfizer and PCORI; consultant for ISDIN, Beiersdorf, Ferndale, L'Oréal, Eli Lilly, Zerigo Health, Cantabria labs and Skinosive and as a speaker on general education sessions for La Roche-Posay, Cantabria labs, Pierre Fabre, NAOS, Uriage and Pfizer. These conflicts were transparently disclosed prior to study initiation and documented. The Delphi process was independently facilitated to ensure balanced input. All other authors declare that they have no conflict of interest.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

ETHICAL APPROVAL

No ethical approval was required because this Delphi-based study involved only expert opinions via questionnaire rounds. No patient data, human biological samples or clinical interventions were involved.

ETHICS STATEMENT

All participants were informed about the study's purpose and provided consent prior to initiating the Delphi process. All panellists received an email invitation and completed the questionnaire only after providing informed consent via a consent statement embedded at the beginning of the survey. In surveying professional experts, no personal or sensitive data were collected.

ORCID

Rashmi Sarkar

14. Agarwal SB, Godse K, Patil S, Nadkarni N. Knowledge and attitude of general population toward effects of sun exposure and use of sunscreens. *Indian J Dermatol*. 2018;63(4):285–91.
15. Song H, Beckles A, Salian P, Porter ML. Sunscreen recommendations for patients with skin of color in the popular press and in the dermatology clinic. *Int J Womens Dermatol*. 2021;7(2):165–70.
16. Zhou C, Lee C, Salas J, Luke J. Guide to tinted sunscreens in skin of color. *Int J Dermatol*. 2024;63(3):272–6.
17. Schneider SL, Lim HW. A review of inorganic UV filters zinc oxide and titanium dioxide. *Photodermatol Photoimmunol Photomed*. 2019;35(6):442–6.
18. Seit  S, Deshayes P, Dr no B, Misery L, Reygagne P, Saiag P, et al. Interest of corrective makeup in the management of patients in dermatology. *Clin Cosmet Investig Dermatol*. 2012;5:123–8.
19. Brown A, Passeron T, Granger C, Gilaberte Y, Trullas C, Piquero-Casals J, et al. An evidence-driven classification of non-filtering ingredients for topical photoprotection. *Br J Dermatol*. 2025;192(6):1132–4.
20. Lim HW, Kohli I, Ruvolo E, Kolbe L, Hamzavi IH. Impact of visible light on skin health: the role of antioxidants and free radical quenchers in skin protection. *J Am Acad Dermatol*. 2022;86(3S):S27–S37.
21. Passeron T, Lim HW, Goh CL, Kang HY, Ly F, Morita A, et al. Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel. *J Eur Acad Dermatol Venereol*. 2021;35(7):1460–9.
22. Lee DJ, Lee J, Ha J, Park KC, Ortonne JP, Kang HY. Defective barrier function in melasma skin. *J Eur Acad Dermatol Venereol*. 2012;26(12):1533–7.
23. Wang Y, Zhao J, Jiang L, Mu Y. The application of skin care product in melasma treatment. *Clin Cosmet Investig Dermatol*. 2021;14:1165–71.
24. Bronzina E, Clement A, Marie B, Fook Chong KT, Faure P, Passeron T. Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone. *J Eur Acad Dermatol Venereol*. 2020;34(4):897–903.
25. Schwartz C, Jan A, Zito PM. Hydroquinone. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539693/> (last accessed 29 January 2025).
26. Bhattar PA, Zawar VP, Godse KV, Patil SP, Nadkarni NJ, Gautam MM. Exogenous ochronosis. *Indian J Dermatol*. 2015;60(6):537–43.
27. Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-based treatment for melasma: expert opinion and a review. *Dermatol Ther (Heidelb)*. 2014;4(2):165–86.
28. Vadukul DP, Rathwa M, Varu DP, Apurva P, Sunidhi RG, Nipul VV, et al. Comparison of effectiveness and ADR profile of topical triple combination preparation containing fluocinonide acetone 0.01% versus mometasone furoate 0.1% in treatment of melasma – a split face study. *Eur J Cardiovasc Med*. 2024;14(5):115–9.
29. Grimes PE, Bhawan J, Guevara IL, Col n LE, Johnson LA, Gottschalk RW, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. *J Am Acad Dermatol*. 2010;62(6):962–7.
30. Albzeia W, AlRashidi R, Alkandari D, Sadan M, Alkandari A, Alkanderi JJ, et al. Azelaic acid versus hydroquinone for managing patients with melasma: systematic review and meta-analysis of randomized controlled trials. *Cureus*. 2023;15(7):e41796.
31. Gao TW, Gu H, He L, Lei TC, Li M, Li TN, et al. Consensus on the diagnosis and treatment of melasma in China (2021 version)#. *Int J Dermatol Venereol*. 2021;4(3):133–9.
32. Correia G, Magina S. Efficacy of topical vitamin C in melasma and photoaging: a systematic review. *J Cosmet Dermatol*. 2023;22(7):1938–45.
33. Passeron T, Picardo M. Melasma, a photoaging disorder. *Pigment Cell Melanoma Res*. 2018;31(4):461–5.
34. Al-Niaimi F, Chiang NYZ. Topical vitamin C and the skin: mechanisms of action and clinical applications. *J Clin Aesthet Dermatol*. 2017;10(7):14–7.
35. Desai S, Chan L, Handog E, Djojoseputro L, Lim J, Ling R, et al. Optimizing melasma management with topical tranexamic acid: an expert consensus. *J Drugs Dermatol*. 2023;22(4):386–92.
36. Zhang L, Tan WQ, Fang QQ, Zhao WY, Zhao QM, Gao J, et al. Tranexamic acid for adults with melasma: a systematic review and meta-analysis. *Biomed Res Int*. 2018;2018:1683414.
37. Ferra OM, Marlyn GK, Herry EJP, Alexandro IC, Lidya T, Joan AT, et al. Comparative efficacy of topical 10% versus 5% tranexamic acid in treatment of women with melasma: a double-blind randomized controlled trial. *Universa Med*. 2024;43(2):213–9.
38. Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: a focused review on drug administration routes. *J Cosmet Dermatol*. 2023;22:1197–206.
39. Saka S, Rao GRR, Komaram RB, Kotha S, Tatavarthi R, Chitturi LP. Efficacy of 10% 699 topical tranexamic acid in melasma – A randomized placebo-controlled split face 700 study. *Int J Pharm Sci Res*. 2019;66:2583–6.
40. Ocampo-Candiani J, Alas-Carbajal R, Bonifaz-Araujo JF, Mar n-Castro H, Valenzuela-Ahumada F, V liz-Barandiar n JL, et al. Latin American consensus on the treatment of melasma. *Int J Dermatol*. 2025;64(3):499–512.
41. Tantanarigul P, Sripha A, Chongmelaxme B. The efficacy of topical cosmetic containing alpha-arbutin 5% and kojic acid 2% compared with triple combination cream for the treatment of melasma: a split-face, evaluator-blinded randomized pilot study. *J Cosmet Dermatol*. 2025;24(1):e16562.
42. Liyanage A, Liyanage G, Sirimanna G, Sch rer N. Comparative study on depigmenting agents in skin of color. *J Clin Aesthet Dermatol*. 2022;15(2):12–7.
43. Choudhary S, Joshi R, Sen D. Evaluating the use of an advance lotion for addressing skin hyperpigmentation. *IP Indian J Clin Exp Dermatol*. 2024;10(3):333–9.
44. Chang YF, Lee TL, Oyerinde O, Desai SR, Aljabban A, Bay CP, et al. Efficacy and safety of topical agents in the treatment of melasma: what's evidence? A systematic review and meta-analysis. *J Cosmet Dermatol*. 2023;22(4):1168–76.
45. Chen Z, Huang L. Different administration routes of tranexamic acid in the treatment of melasma. *Chin J Plast Reconstr Surg*. 2024;6(3):154–8.
46. Wang WJ, Wu TY, Tu YK, Kuo KL, Tsai CY, Chie WC. The optimal dose of oral tranexamic acid in melasma: a network meta-analysis. *Indian J Dermatol Venereol Leprol*. 2023;89(2):189–94.
47. Del Rosario E, Florez-Pollack S, Zapata L Jr, Hernandez K, Tovar-Garza A, Rodrigues M, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. *J Am Acad Dermatol*. 2018;78(2):363–9.
48. Keshavamurthy V, Bhattacharjee R, Hanumanth V, Bishnoi A, Vinay K, Kumar A, et al. P70 a randomized open-label study to compare two different dosage regimens of oral tranexamic acid in treatment of moderate-to-severe facial melasma. *Br J Dermatol*. 2023;188(Suppl 4):ljad113.098.
49. Sarkar R, Narayan RV, Vinay K, Lakhani R, Sinha S, Mysore V, et al. Prescribing practices of tranexamic acid for melasma: Delphi consensus from the pigmentary disorders society. *Indian J Dermatol Venereol Leprol*. 2023;90(1):41–5.
50. Malankar TE, Thomas M, Gangawane AA, Rajpurohit L. Melatonin: a paradigm shift in the management of melasma. *Am J Cosmet Surg*. 2025;42(2):108–15.
51. Sarkar R, Verma B, Mendiratta V. Use of oral melatonin in recalcitrant melasma. *Int J Dermatol*. 2024;63(8):1111–2.
52. Sarkar R, Lakhani R. Chemical peels for melasma: a systematic review. *Dermatol Surg*. 2024;50(7):656–61.
53. Sadagopan K, Chintakula N. Analysis of response of epidermal melasma to 70% glycolic acid peel. *Int J Res Dermatol*. 2020;6(2):174–7.
54. Sarkar R, Arsiwala S, Dubey N, Sonthalia S, Das A, Arya L, et al. Chemical peels in melasma: a review with consensus recommendations by Indian pigmentary expert group. *Indian J Dermatol*. 2017;62(6):578–84.
55. Sahu P, Dayal S, Bhardwaj N. Topical 5% tranexamic acid with 30% glycolic acid peel: an useful combination for accelerating the improvement in melasma. *Dermatol Ther*. 2021;34(6):e15107.

56. Kadu PP, Laul RA. 80% lactic acid peel versus 50% glycolic acid peel for melasma: a randomised clinical trial. *Indian J Dermatol.* 2025;70(3):152–6.
57. de Andrade ACDV, Coqueiro RDS, Pithon MM, Leite MF. Peeling with retinoic acid in microemulsion for treatment of melasma: a double-blind randomized controlled clinical study. *J Cosmet Dermatol.* 2024;23(2):479–85.
58. Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients. *Dermatol Surg.* 2004;30(5):756–60.
59. Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. *J Cutan Aesthet Surg.* 2012;5(4):247–53.
60. Mashiko T, Oka A, Osawa E, Koshima I. A deceptively simple solution for refractory melasma: glycolic acid peels and hydroquinone at home. *Plast Reconstr Surg Glob Open.* 2017;5(5):e1335.
61. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. *Dermatol Surg.* 2002;28(9):828–32.
62. Sarkar R, Garg V, Bansal S, Sethi S, Gupta C. Comparative evaluation of efficacy and tolerability of glycolic acid, salicylic mandelic acid, and phytic acid combination peels in melasma. *Dermatol Surg.* 2016;42(3):384–91.
63. Cassiano DP, Espósito ACC, da Silva CN, Lima PB, Dias JAF, Hassun K, et al. Update on melasma—part II: treatment. *Dermatol Ther (Heidelb).* 2022;12(9):1989–2012.
64. Shah SD, Aurangabadkar SJ. Laser toning in melasma. *J Cutan Aesthet Surg.* 2019;12(2):76–84.
65. Ma W, Gao Q, Liu J, Zhong X, Xu T, Wu Q, et al. Efficacy and safety of laser-related therapy for melasma: a systematic review and network meta-analysis. *J Cosmet Dermatol.* 2023;22(11):2910–24.
66. Sarkar R, Aurangabadkar S, Salim T, Das A, Shah S, Majid I, et al. Lasers in melasma: a review with consensus recommendations by Indian pigmentary expert group. *Indian J Dermatol.* 2017;62(6):585–90.
67. Park SJ, Park JW, Seo SJ, Park KY. Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: a single center, prospective, split-face trial. *Dermatol Ther.* 2022;35(3):e15287.
68. Masub N, Nguyen JK, Austin E, Jagdeo J. The vascular component of melasma: a systematic review of laboratory, diagnostic, and therapeutic evidence. *Dermatol Surg.* 2020;46(12):1642–50.
69. Bailey AJM, Li HO-